Cargando…

Transarterial Embolization for Treatment of Symptomatic Polycystic Liver Disease: More than 2-year Follow-up

BACKGROUND: Currently, treatment of symptomatic polycystic liver disease (PLD) is still a challenging problem, especially for these patients who are not feasible for surgery. Minimally invasive options such as laparoscopic fenestration and percutaneous cyst aspiration with sclerotherapy demonstrated...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jin-Long, Yuan, Kai, Wang, Mao-Qiang, Yan, Jie-Yu, Xin, Hai-Nan, Wang, Yan, Liu, Feng-Yong, Bai, Yan-Hua, Wang, Zhi-Jun, Duan, Feng, Fu, Jin-Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555128/
https://www.ncbi.nlm.nih.gov/pubmed/28776546
http://dx.doi.org/10.4103/0366-6999.211882
_version_ 1783256890541604864
author Zhang, Jin-Long
Yuan, Kai
Wang, Mao-Qiang
Yan, Jie-Yu
Xin, Hai-Nan
Wang, Yan
Liu, Feng-Yong
Bai, Yan-Hua
Wang, Zhi-Jun
Duan, Feng
Fu, Jin-Xin
author_facet Zhang, Jin-Long
Yuan, Kai
Wang, Mao-Qiang
Yan, Jie-Yu
Xin, Hai-Nan
Wang, Yan
Liu, Feng-Yong
Bai, Yan-Hua
Wang, Zhi-Jun
Duan, Feng
Fu, Jin-Xin
author_sort Zhang, Jin-Long
collection PubMed
description BACKGROUND: Currently, treatment of symptomatic polycystic liver disease (PLD) is still a challenging problem, especially for these patients who are not feasible for surgery. Minimally invasive options such as laparoscopic fenestration and percutaneous cyst aspiration with sclerotherapy demonstrated disappointing results due to multiple lesions. Because the cysts in PLD are mostly supplied from hepatic arteries but not from portal veins, transcatheter arterial embolization (TAE) of the hepatic artery branches that supply the major hepatic cysts can lead to shrinkage of the cyst and liver size, relieve symptoms, and improve nutritional status. This study aimed to evaluate the effectiveness of TAE with a mixture of N-butyl-2-cyanoacrylate (NBCA) and iodized oil for patients with severe symptomatic PLD during a more than 2-year follow-up. METHODS: Institutional review board had approved this study. Written informed consent was obtained from all patients. From February 2007 to December 2014, twenty-three patients (20 women and 3 men; mean age, 49.0 ± 14.5 years) infeasible for surgical treatments underwent TAE. Changes in the abdominal circumferences, volumes of intrahepatic cysts, hepatic parenchyma volume, and whole liver, clinical symptoms, laboratory data, and complications were evaluated after TAE. RESULTS: Technical success was achieved in all cases. No procedure-related major complications occurred. The median follow-up period after TAE was 48.5 months (interquartile range, 30.0–72.0 months). PLD-related severe symptoms were improved remarkably in 86% of the treated patients; TAE failed to benefit in four patients (four patients did not benefit from TAE). The mean maximum abdominal circumference decreased significantly from 106.0 ± 8.0 cm to 87.0 ± 15.0 cm (P = 0.021). The mean intrahepatic cystic volume reduction rates compared with pre-TAE were 36% at 12 months, 37% at 24 months, and 38% at 36 months after TAE (P < 0.05). The mean liver volume reduction rates were 32% at 12 months, 31% at 24 months, and 33% at 36 months (P < 0.05). CONCLUSIONS: TAE with the mixture of NBCA and iodized oil appears to be a safe and effective treatment method for patients with symptomatic PLD, especially for those who are not good candidates for surgical treatments, to improve both hepatic volume and hepatic cysts volume.
format Online
Article
Text
id pubmed-5555128
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-55551282017-08-31 Transarterial Embolization for Treatment of Symptomatic Polycystic Liver Disease: More than 2-year Follow-up Zhang, Jin-Long Yuan, Kai Wang, Mao-Qiang Yan, Jie-Yu Xin, Hai-Nan Wang, Yan Liu, Feng-Yong Bai, Yan-Hua Wang, Zhi-Jun Duan, Feng Fu, Jin-Xin Chin Med J (Engl) Original Article BACKGROUND: Currently, treatment of symptomatic polycystic liver disease (PLD) is still a challenging problem, especially for these patients who are not feasible for surgery. Minimally invasive options such as laparoscopic fenestration and percutaneous cyst aspiration with sclerotherapy demonstrated disappointing results due to multiple lesions. Because the cysts in PLD are mostly supplied from hepatic arteries but not from portal veins, transcatheter arterial embolization (TAE) of the hepatic artery branches that supply the major hepatic cysts can lead to shrinkage of the cyst and liver size, relieve symptoms, and improve nutritional status. This study aimed to evaluate the effectiveness of TAE with a mixture of N-butyl-2-cyanoacrylate (NBCA) and iodized oil for patients with severe symptomatic PLD during a more than 2-year follow-up. METHODS: Institutional review board had approved this study. Written informed consent was obtained from all patients. From February 2007 to December 2014, twenty-three patients (20 women and 3 men; mean age, 49.0 ± 14.5 years) infeasible for surgical treatments underwent TAE. Changes in the abdominal circumferences, volumes of intrahepatic cysts, hepatic parenchyma volume, and whole liver, clinical symptoms, laboratory data, and complications were evaluated after TAE. RESULTS: Technical success was achieved in all cases. No procedure-related major complications occurred. The median follow-up period after TAE was 48.5 months (interquartile range, 30.0–72.0 months). PLD-related severe symptoms were improved remarkably in 86% of the treated patients; TAE failed to benefit in four patients (four patients did not benefit from TAE). The mean maximum abdominal circumference decreased significantly from 106.0 ± 8.0 cm to 87.0 ± 15.0 cm (P = 0.021). The mean intrahepatic cystic volume reduction rates compared with pre-TAE were 36% at 12 months, 37% at 24 months, and 38% at 36 months after TAE (P < 0.05). The mean liver volume reduction rates were 32% at 12 months, 31% at 24 months, and 33% at 36 months (P < 0.05). CONCLUSIONS: TAE with the mixture of NBCA and iodized oil appears to be a safe and effective treatment method for patients with symptomatic PLD, especially for those who are not good candidates for surgical treatments, to improve both hepatic volume and hepatic cysts volume. Medknow Publications & Media Pvt Ltd 2017-08-20 /pmc/articles/PMC5555128/ /pubmed/28776546 http://dx.doi.org/10.4103/0366-6999.211882 Text en Copyright: © 2017 Chinese Medical Journal http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Zhang, Jin-Long
Yuan, Kai
Wang, Mao-Qiang
Yan, Jie-Yu
Xin, Hai-Nan
Wang, Yan
Liu, Feng-Yong
Bai, Yan-Hua
Wang, Zhi-Jun
Duan, Feng
Fu, Jin-Xin
Transarterial Embolization for Treatment of Symptomatic Polycystic Liver Disease: More than 2-year Follow-up
title Transarterial Embolization for Treatment of Symptomatic Polycystic Liver Disease: More than 2-year Follow-up
title_full Transarterial Embolization for Treatment of Symptomatic Polycystic Liver Disease: More than 2-year Follow-up
title_fullStr Transarterial Embolization for Treatment of Symptomatic Polycystic Liver Disease: More than 2-year Follow-up
title_full_unstemmed Transarterial Embolization for Treatment of Symptomatic Polycystic Liver Disease: More than 2-year Follow-up
title_short Transarterial Embolization for Treatment of Symptomatic Polycystic Liver Disease: More than 2-year Follow-up
title_sort transarterial embolization for treatment of symptomatic polycystic liver disease: more than 2-year follow-up
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555128/
https://www.ncbi.nlm.nih.gov/pubmed/28776546
http://dx.doi.org/10.4103/0366-6999.211882
work_keys_str_mv AT zhangjinlong transarterialembolizationfortreatmentofsymptomaticpolycysticliverdiseasemorethan2yearfollowup
AT yuankai transarterialembolizationfortreatmentofsymptomaticpolycysticliverdiseasemorethan2yearfollowup
AT wangmaoqiang transarterialembolizationfortreatmentofsymptomaticpolycysticliverdiseasemorethan2yearfollowup
AT yanjieyu transarterialembolizationfortreatmentofsymptomaticpolycysticliverdiseasemorethan2yearfollowup
AT xinhainan transarterialembolizationfortreatmentofsymptomaticpolycysticliverdiseasemorethan2yearfollowup
AT wangyan transarterialembolizationfortreatmentofsymptomaticpolycysticliverdiseasemorethan2yearfollowup
AT liufengyong transarterialembolizationfortreatmentofsymptomaticpolycysticliverdiseasemorethan2yearfollowup
AT baiyanhua transarterialembolizationfortreatmentofsymptomaticpolycysticliverdiseasemorethan2yearfollowup
AT wangzhijun transarterialembolizationfortreatmentofsymptomaticpolycysticliverdiseasemorethan2yearfollowup
AT duanfeng transarterialembolizationfortreatmentofsymptomaticpolycysticliverdiseasemorethan2yearfollowup
AT fujinxin transarterialembolizationfortreatmentofsymptomaticpolycysticliverdiseasemorethan2yearfollowup